CytoMed Therapeutics Minority Interest

The latest minority interest for GDTC is $310K as of December 2025. That compares with $57K in the prior-year period — up 442.6% year over year. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GDTC's minority interest moved from $57K to $310K — a 442.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CytoMed Therapeutics's operating scale or balance-sheet position.

A minority interest figure of $310K for GDTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GDTC's minority interest ($310K), review year-over-year change from $57K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.